Abivax up on mixed HIV data

Submitted by admin on July 4, 2018 - 10:02am

Source:

Biopharma Dive

News Tags:

Headline:

snippet:

Paris-based Abivax announced topline results from the second cohort of its Phase 2a study of ABX464 in patients with HIV, with mixed findings.

Search form